The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 01, 2025

Filed:

Jul. 31, 2020
Applicant:

Adaptive Biotechnologies Corporation, Seattle, WA (US);

Inventors:

Harlan S. Robins, Seattle, WA (US);

Thomas M. Snyder, San Bruno, CA (US);

Mark Klinger, Seattle, WA (US);

Jonathan M. Carlson, Redmond, WA (US);

Julia Greissl, Redmond, WA (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/65 (2006.01); A61K 9/00 (2006.01); A61K 31/43 (2006.01); A61K 31/431 (2006.01); A61K 31/53 (2006.01); A61P 31/04 (2006.01); G01N 33/569 (2006.01); G16B 40/00 (2019.01); C07K 14/725 (2006.01);
U.S. Cl.
CPC ...
A61K 31/65 (2013.01); A61K 9/0019 (2013.01); A61K 31/43 (2013.01); A61K 31/431 (2013.01); A61K 31/53 (2013.01); A61P 31/04 (2018.01); G01N 33/56972 (2013.01); G16B 40/00 (2019.02); G01N 2333/7051 (2013.01); G01N 2800/24 (2013.01);
Abstract

Provided are methods for assessing T cell receptor β chain complementary determining region 3 (TCRβ CDR3) sequences. In certain embodiments, the methods comprise assessing TCRβ CDR3 sequences determined from a sample obtained from a subject having or suspected of having a tick bite for the presence or absence of one or more TCRβ CDR3 sequences set forth in the present disclosure. According to some embodiments, at the time of the assessing, the subject is seronegative for Lyme disease and/or has one or more non-specific symptoms consistent with Lyme disease. Also provided are methods comprising administering a Lyme disease therapy to a subject identified as comprising T cells that express a T cell receptor β chain (TCRβ) comprising a TCRβ CDR3 sequence set forth in the present disclosure.


Find Patent Forward Citations

Loading…